ABBOTT LABORATORIES Proceeds from Long-Term Debt Issued
ABBOTT LABORATORIES (ABT) reported Proceeds from Long-Term Debt Issued of $19.86 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-04-29
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $19.86B, a 1985900.00% increase year-over-year.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $2.00M, a 99.10% decline year-over-year.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $1.00M.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for fiscal 2021 was $4.00M, a 99.69% decline from fiscal 2020.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for fiscal 2020 was $1.28B, a 30.46% decline from fiscal 2019.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for fiscal 2019 was $1.84B, a 54.05% decline from fiscal 2018.
- ABBOTT LABORATORIES proceeds from issuance of long-term debt for fiscal 2018 was $4.01B, a 40.54% decline from fiscal 2017.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-03-31 | $19.86B 10-Q · filed 2026-04-29 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $2.00M derived: sum of 2 quarters · filed 2025-10-29 | $3.00M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $3.00M 10-Q · filed 2025-07-30 | ||
| 2025-03-31 | $1.00M 10-Q · filed 2026-04-29 | |||
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $222.00M derived: sum of 2 quarters · filed 2025-10-29 | $222.00M 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $221.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $221.00M 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-30 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.00M 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $1.00M 10-Q · filed 2024-07-31 | |||
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $7.00M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | $6.00M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $4.00M derived: sum of 2 quarters · filed 2022-11-01 | $4.00M 10-K · filed 2022-02-18 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | |||
| 2020-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $2.00M derived: sum of 2 quarters · filed 2022-02-18 | $1.28B 10-K · filed 2022-02-18 | |
| 2020-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.28B 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $1.28B 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $1.84B 10-K · filed 2022-02-18 | |||
| 2018-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $4.01B 10-K · filed 2021-02-19 | ||
| 2018-09-30 | $4.01B 10-Q · filed 2019-10-31 | |||
| 2017-12-31 | $6.74B 10-K · filed 2020-02-21 | |||
| 2016-12-31 | $14.93B 10-K · filed 2019-02-22 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $0.00 derived: sum of 2 quarters · filed 2018-02-16 | $0.00 derived: sum of 3 quarters · filed 2018-02-16 | $2.48B 10-K · filed 2018-02-16 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $2.48B 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $2.48B 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | $2.48B 10-Q · filed 2016-05-04 | |||
| 2013-12-31 | $9.00M 10-K · filed 2016-02-19 | |||
| 2012-12-31 | $14.70B 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $1.00B 10-K · filed 2014-02-21 | |||
| 2010-12-31 | $1.00B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $1.00B derived: sum of 2 quarters · filed 2013-02-15 | $4.00B 10-K · filed 2013-02-15 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $3.00B 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $3.00B 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $0.00 derived: sum of 2 quarters · filed 2012-02-21 | $0.00 derived: sum of 3 quarters · filed 2012-02-21 | $3.00B 10-K · filed 2012-02-21 |
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $0.00 derived: sum of 2 quarters · filed 2010-11-05 | $3.00B 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-05 | $3.00B 10-Q · filed 2010-08-05 | ||
| 2009-03-31 | $3.00B 10-Q · filed 2010-05-04 | |||
| 2007-12-31 | $3.50B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |